Cargando…

Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is an invariably fatal neurodegenerative disease with limited therapeutic options. There is an urgent need for novel biomarkers to be used as surrogates for new therapeutic trials and disease monitoring. In this study, we sought to systematically study creatine ki...

Descripción completa

Detalles Bibliográficos
Autores principales: Kittipeerapat, Natsinee, Fabian, Rachel, Bernsen, Sarah, Weydt, Patrick, Castro-Gomez, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380590/
https://www.ncbi.nlm.nih.gov/pubmed/37511443
http://dx.doi.org/10.3390/ijms241411682
_version_ 1785080233646358528
author Kittipeerapat, Natsinee
Fabian, Rachel
Bernsen, Sarah
Weydt, Patrick
Castro-Gomez, Sergio
author_facet Kittipeerapat, Natsinee
Fabian, Rachel
Bernsen, Sarah
Weydt, Patrick
Castro-Gomez, Sergio
author_sort Kittipeerapat, Natsinee
collection PubMed
description Amyotrophic lateral sclerosis (ALS) is an invariably fatal neurodegenerative disease with limited therapeutic options. There is an urgent need for novel biomarkers to be used as surrogates for new therapeutic trials and disease monitoring. In this study, we sought to systematically study creatine kinase isoenzyme MB (CK-MB) in a real-world cohort of ALS patients, assess the diagnostic performance, and evaluate its association with other laboratory and clinical parameters. We reviewed data from 194 consecutive patients that included 130 ALS patients and 64 disease control patients (primary lateral sclerosis [PLS], benign fasciculations syndrome [BFS], Huntington’s disease [HD] and Alzheimer’s disease [AD]). CK-MB was elevated in the sera of more than half of all patients with ALS. In patients with spinal-onset ALS, CK-MB levels were significantly higher than in patients with other neurodegenerative diseases. Patients with slower rates of functional decline had a significantly higher baseline CK-MB. Furthermore, CK-MB elevations correlated with cardiac troponin T (cTnT) and with revised ALS Functional Rating Scale (ALSFRS-R) bulbar subcategory. We posit that measuring CK-MB in ALS patients in a complimentary fashion could potentially aid in the diagnostic workup of ALS and help discriminate the disease from some ALS mimics and other neurodegenerative diseases. CK-MB levels also may provide valuable prognostic information regarding disease aggressiveness as well as correlations with specific phenotypic presentations.
format Online
Article
Text
id pubmed-10380590
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103805902023-07-29 Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis Kittipeerapat, Natsinee Fabian, Rachel Bernsen, Sarah Weydt, Patrick Castro-Gomez, Sergio Int J Mol Sci Article Amyotrophic lateral sclerosis (ALS) is an invariably fatal neurodegenerative disease with limited therapeutic options. There is an urgent need for novel biomarkers to be used as surrogates for new therapeutic trials and disease monitoring. In this study, we sought to systematically study creatine kinase isoenzyme MB (CK-MB) in a real-world cohort of ALS patients, assess the diagnostic performance, and evaluate its association with other laboratory and clinical parameters. We reviewed data from 194 consecutive patients that included 130 ALS patients and 64 disease control patients (primary lateral sclerosis [PLS], benign fasciculations syndrome [BFS], Huntington’s disease [HD] and Alzheimer’s disease [AD]). CK-MB was elevated in the sera of more than half of all patients with ALS. In patients with spinal-onset ALS, CK-MB levels were significantly higher than in patients with other neurodegenerative diseases. Patients with slower rates of functional decline had a significantly higher baseline CK-MB. Furthermore, CK-MB elevations correlated with cardiac troponin T (cTnT) and with revised ALS Functional Rating Scale (ALSFRS-R) bulbar subcategory. We posit that measuring CK-MB in ALS patients in a complimentary fashion could potentially aid in the diagnostic workup of ALS and help discriminate the disease from some ALS mimics and other neurodegenerative diseases. CK-MB levels also may provide valuable prognostic information regarding disease aggressiveness as well as correlations with specific phenotypic presentations. MDPI 2023-07-20 /pmc/articles/PMC10380590/ /pubmed/37511443 http://dx.doi.org/10.3390/ijms241411682 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kittipeerapat, Natsinee
Fabian, Rachel
Bernsen, Sarah
Weydt, Patrick
Castro-Gomez, Sergio
Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis
title Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis
title_full Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis
title_fullStr Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis
title_full_unstemmed Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis
title_short Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis
title_sort creatine kinase mb isoenzyme is a complementary biomarker in amyotrophic lateral sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380590/
https://www.ncbi.nlm.nih.gov/pubmed/37511443
http://dx.doi.org/10.3390/ijms241411682
work_keys_str_mv AT kittipeerapatnatsinee creatinekinasembisoenzymeisacomplementarybiomarkerinamyotrophiclateralsclerosis
AT fabianrachel creatinekinasembisoenzymeisacomplementarybiomarkerinamyotrophiclateralsclerosis
AT bernsensarah creatinekinasembisoenzymeisacomplementarybiomarkerinamyotrophiclateralsclerosis
AT weydtpatrick creatinekinasembisoenzymeisacomplementarybiomarkerinamyotrophiclateralsclerosis
AT castrogomezsergio creatinekinasembisoenzymeisacomplementarybiomarkerinamyotrophiclateralsclerosis